Generate Biomedicines to Participate in Goldman Sachs Global Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2026
0mins
Source: PRnewswire
- Conference Participation Announcement: Generate Biomedicines (NASDAQ:GENB) has announced its participation in the Goldman Sachs Global Healthcare Conference on June 8, 2026, with a live webcast expected to enhance visibility and trust among investors.
- Innovative Platform Overview: The company focuses on the intersection of machine learning, biological engineering, and medicine, aiming to accelerate drug development through its generative platform to create superior therapeutic solutions that meet urgent patient needs.
- Pipeline Expansion: By integrating computational design with large-scale biological experimentation, the platform has successfully generated a variety of therapeutic solutions targeting health challenges that traditional methods struggle to address, showcasing significant innovation potential and market competitiveness.
- Company Background Summary: Founded in 2018, Generate Biomedicines is leading a fundamental shift from drug discovery to drug generation, committed to developing novel therapies for hard-to-drug targets, thereby advancing the progress and development of the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GENB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GENB
Wall Street analysts forecast GENB stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 14.700
Low
Averages
High
Current: 14.700
Low
Averages
High
About GENB
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HarbourVest Partners Acquires Stake in Generate Biomedicines
- New Investment Disclosure: HarbourVest Partners disclosed a new position in Generate Biomedicines (GENB) by acquiring 1,722,210 shares in Q1 2026, with an estimated transaction value of $21.03 million, indicating strong conviction in the company's future.
- Position Value Analysis: As of March 31, 2026, the value of Generate Biomedicines' position was $21.53 million, representing 21% of HarbourVest's reportable AUM, highlighting the significance of this investment in their portfolio.
- Financial Overview: Generate Biomedicines has a market capitalization of $2 billion, and despite a revenue decline to $7.2 million year-over-year, the company holds $516.6 million in cash and equivalents, providing a runway into the first half of 2028.
- Clinical Progress and Strategy: The lead candidate GB-0895 is advancing through Phase 3 trials, with management emphasizing progress across multiple programs, showcasing the company's potential in drug development and AI-driven discovery platforms.
See More
HarbourVest Acquires 1.72 Million Shares of Generate Biomedicines
- Share Acquisition: HarbourVest initiated a position in Generate Biomedicines by acquiring 1,722,210 shares in Q1 2026, with an estimated transaction value of $21.03 million, indicating strong conviction in the company's potential, especially given its clinical pipeline advancements.
- Asset Growth: As of March 31, 2026, HarbourVest's position in Generate was valued at $21.53 million, reflecting a 21% increase in reportable assets under management, driven by both share purchases and favorable price movements in the market.
- Financial Position: Generate Biomedicines ended the quarter with $516.6 million in cash and equivalents, despite a revenue decline from $8.8 million to $7.2 million year-over-year, as the company ramps up investments in late-stage clinical programs, showcasing its long-term growth potential.
- Clinical Progress: The lead candidate GB-0895 is advancing through Phase 3 trials for severe asthma, while oncology candidates are expected to initiate key clinical activities later this year, highlighting the company's ongoing commitment to drug development and strategic positioning in the biotech sector.
See More
Generate Biomedicines to Participate in Goldman Sachs Global Healthcare Conference
- Conference Participation Announcement: Generate Biomedicines (NASDAQ:GENB) has announced its participation in the Goldman Sachs Global Healthcare Conference on June 8, 2026, with a live webcast expected to enhance visibility and trust among investors.
- Innovative Platform Overview: The company focuses on the intersection of machine learning, biological engineering, and medicine, aiming to accelerate drug development through its generative platform to create superior therapeutic solutions that meet urgent patient needs.
- Pipeline Expansion: By integrating computational design with large-scale biological experimentation, the platform has successfully generated a variety of therapeutic solutions targeting health challenges that traditional methods struggle to address, showcasing significant innovation potential and market competitiveness.
- Company Background Summary: Founded in 2018, Generate Biomedicines is leading a fundamental shift from drug discovery to drug generation, committed to developing novel therapies for hard-to-drug targets, thereby advancing the progress and development of the biopharmaceutical industry.
See More
Generate Biomedicines Reports Q1 2026 Financial Results and Clinical Progress
- Improved Financial Position: As of March 31, 2026, Generate reported cash and cash equivalents of $516.6 million, a significant increase from $221.5 million on December 31, 2025, reflecting the successful completion of its IPO which raised $369.3 million in net proceeds, thereby securing funding for future operations.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $57.8 million, up from $46.8 million in Q1 2025, primarily driven by continued investment in the GB-0895 program, indicating a strategic focus on severe asthma treatment.
- Significant Clinical Progress: Generate is advancing its GB-0895 program into Phase 3 clinical trials for severe asthma and is conducting a Phase 1b trial for COPD, which is expected to enhance the company's competitive position in the respiratory disease market.
- Widening Net Loss: The net loss for Q1 2026 was $61.7 million, compared to $44.3 million in Q1 2025, largely due to increased stock-based compensation expenses, which may negatively impact investor confidence.
See More
Generate Biomedicines Reports Q1 Highlights and Progress
- Improved Financial Position: As of March 31, 2026, Generate Biomedicines reported $516.6 million in cash and cash equivalents, a significant increase from $221.5 million as of December 31, 2025, indicating a strong post-IPO financial position that is expected to fund operations into the first half of 2028.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $57.8 million, up from $46.8 million in the same period of 2025, primarily driven by continued investment in the GB-0895 program, reflecting the company's strategic focus on critical therapeutic areas.
- Clinical Trial Advancements: The Phase 3 clinical trials for GB-0895 are underway for severe asthma, showing promising progress, while clinical trials for GB-4362 and GB-5267 are also advancing, which is expected to bolster the company's competitive edge in the market.
- Widening Net Loss: The net loss for Q1 2026 was $61.7 million, compared to $44.3 million in Q1 2025, primarily due to increased stock-based compensation and operational costs, highlighting the financial pressures faced by the company as it expands its business.
See More
GENERATE BIOMEDICINES INC REPORTS $61.7 MILLION NET LOSS FOR Q1
- Financial Performance: Generate Biomedicines reported a net loss of $61.7 million for the first quarter.
- Business Focus: The company continues to prioritize advancements in its biomedicine technologies despite the financial setback.
See More
HarbourVest Partners Acquires Stake in Generate Biomedicines
- New Investment Disclosure: HarbourVest Partners disclosed a new position in Generate Biomedicines (GENB) by acquiring 1,722,210 shares in Q1 2026, with an estimated transaction value of $21.03 million, indicating strong conviction in the company's future.
- Position Value Analysis: As of March 31, 2026, the value of Generate Biomedicines' position was $21.53 million, representing 21% of HarbourVest's reportable AUM, highlighting the significance of this investment in their portfolio.
- Financial Overview: Generate Biomedicines has a market capitalization of $2 billion, and despite a revenue decline to $7.2 million year-over-year, the company holds $516.6 million in cash and equivalents, providing a runway into the first half of 2028.
- Clinical Progress and Strategy: The lead candidate GB-0895 is advancing through Phase 3 trials, with management emphasizing progress across multiple programs, showcasing the company's potential in drug development and AI-driven discovery platforms.
See More
HarbourVest Acquires 1.72 Million Shares of Generate Biomedicines
- Share Acquisition: HarbourVest initiated a position in Generate Biomedicines by acquiring 1,722,210 shares in Q1 2026, with an estimated transaction value of $21.03 million, indicating strong conviction in the company's potential, especially given its clinical pipeline advancements.
- Asset Growth: As of March 31, 2026, HarbourVest's position in Generate was valued at $21.53 million, reflecting a 21% increase in reportable assets under management, driven by both share purchases and favorable price movements in the market.
- Financial Position: Generate Biomedicines ended the quarter with $516.6 million in cash and equivalents, despite a revenue decline from $8.8 million to $7.2 million year-over-year, as the company ramps up investments in late-stage clinical programs, showcasing its long-term growth potential.
- Clinical Progress: The lead candidate GB-0895 is advancing through Phase 3 trials for severe asthma, while oncology candidates are expected to initiate key clinical activities later this year, highlighting the company's ongoing commitment to drug development and strategic positioning in the biotech sector.
See More
Generate Biomedicines to Participate in Goldman Sachs Global Healthcare Conference
- Conference Participation Announcement: Generate Biomedicines (NASDAQ:GENB) has announced its participation in the Goldman Sachs Global Healthcare Conference on June 8, 2026, with a live webcast expected to enhance visibility and trust among investors.
- Innovative Platform Overview: The company focuses on the intersection of machine learning, biological engineering, and medicine, aiming to accelerate drug development through its generative platform to create superior therapeutic solutions that meet urgent patient needs.
- Pipeline Expansion: By integrating computational design with large-scale biological experimentation, the platform has successfully generated a variety of therapeutic solutions targeting health challenges that traditional methods struggle to address, showcasing significant innovation potential and market competitiveness.
- Company Background Summary: Founded in 2018, Generate Biomedicines is leading a fundamental shift from drug discovery to drug generation, committed to developing novel therapies for hard-to-drug targets, thereby advancing the progress and development of the biopharmaceutical industry.
See More
Generate Biomedicines Reports Q1 2026 Financial Results and Clinical Progress
- Improved Financial Position: As of March 31, 2026, Generate reported cash and cash equivalents of $516.6 million, a significant increase from $221.5 million on December 31, 2025, reflecting the successful completion of its IPO which raised $369.3 million in net proceeds, thereby securing funding for future operations.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $57.8 million, up from $46.8 million in Q1 2025, primarily driven by continued investment in the GB-0895 program, indicating a strategic focus on severe asthma treatment.
- Significant Clinical Progress: Generate is advancing its GB-0895 program into Phase 3 clinical trials for severe asthma and is conducting a Phase 1b trial for COPD, which is expected to enhance the company's competitive position in the respiratory disease market.
- Widening Net Loss: The net loss for Q1 2026 was $61.7 million, compared to $44.3 million in Q1 2025, largely due to increased stock-based compensation expenses, which may negatively impact investor confidence.
See More
Generate Biomedicines Reports Q1 Highlights and Progress
- Improved Financial Position: As of March 31, 2026, Generate Biomedicines reported $516.6 million in cash and cash equivalents, a significant increase from $221.5 million as of December 31, 2025, indicating a strong post-IPO financial position that is expected to fund operations into the first half of 2028.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $57.8 million, up from $46.8 million in the same period of 2025, primarily driven by continued investment in the GB-0895 program, reflecting the company's strategic focus on critical therapeutic areas.
- Clinical Trial Advancements: The Phase 3 clinical trials for GB-0895 are underway for severe asthma, showing promising progress, while clinical trials for GB-4362 and GB-5267 are also advancing, which is expected to bolster the company's competitive edge in the market.
- Widening Net Loss: The net loss for Q1 2026 was $61.7 million, compared to $44.3 million in Q1 2025, primarily due to increased stock-based compensation and operational costs, highlighting the financial pressures faced by the company as it expands its business.
See More
GENERATE BIOMEDICINES INC REPORTS $61.7 MILLION NET LOSS FOR Q1
- Financial Performance: Generate Biomedicines reported a net loss of $61.7 million for the first quarter.
- Business Focus: The company continues to prioritize advancements in its biomedicine technologies despite the financial setback.
See More
